Skip to main content
Year archive

AMPLIA THERAPEUTICS LIMITED — 2025 filings

All 75 regulatory filings released by AMPLIA THERAPEUTICS LIMITED (ATX) in 2025, sourced directly from the official regulator.

75 Filings
2025 Period
2025 filings (75)
Filing Released Lang
Amplia Enters 2nd Agreement with Drug Screening Co Next Bio 2 pages 131.3KB
Capital/Financing Update
2025-12-18 English
Additional Confirmed Response Reported-Investor Presentation 18 pages 5.6MB
Investor Presentation
2025-12-10 English
Key narmafotinib Patent Granted in the US 2 pages 139.8KB
Regulatory Filings
2025-12-02 English
Half Yearly Report and Accounts 27 pages 1.1MB
Interim / Quarterly Report
2025-11-26 English
Positive Response from US FDA to Amplia's Type D Meeting 2 pages 196.3KB
Capital/Financing Update
2025-11-19 English
Notification regarding unquoted securities - ATX 6 pages 19.6KB
Share Issue/Capital Change
2025-11-09 English
Amplia Commences Trading on U.S. OTCQB Venture Market 2 pages 131.8KB
Capital/Financing Update
2025-10-30 English
Quarterly Activities/Appendix 4C Cash Flow Report 9 pages 359.4KB
Interim / Quarterly Report
2025-10-28 English
Amplia Receives R&D Tax Rebate Totalling $3.77 Million 2 pages 113.8KB
Regulatory Filings
2025-10-27 English
Amplia Therapeutics to Significantly Expand U.S. Presence 2 pages 144.1KB
Capital/Financing Update
2025-10-16 English
ADDITIONAL RESPONSES IN ACCENT PANCREATIC CANCER TRIAL 3 pages 233.5KB
Regulatory Filings
2025-10-08 English
Notification of cessation of securities - ATX 4 pages 14.8KB
Share Issue/Capital Change
2025-10-07 English
Patent Allowance for Key Narmafotinib Patent in US 2 pages 163.2KB
Regulatory Filings
2025-09-29 English
Notification of cessation of securities - ATX 4 pages 14.8KB
Share Issue/Capital Change
2025-09-07 English
Change of Director's Interest Notice - Jane Bell 4 pages 300.2KB
Director's Dealing
2025-09-07 English
Change of Director's Interest Notice - Robert Peach 4 pages 342.3KB
Director's Dealing
2025-09-07 English
Change of Director's Interest Notice - Chris Burns 4 pages 340.4KB
Director's Dealing
2025-09-07 English
Change of Director's Interest Notice - Warwick Tong 4 pages 343.8KB
Director's Dealing
2025-09-07 English
FIRST PATIENT DOSED IN NEW PANCREATIC CANCER TRIAL 2 pages 195.0KB
Regulatory Filings
2025-09-03 English
NARMAFOTINIB ADOPTED AS NONPROPRIETARY DRUG NAME IN USA 2 pages 185.1KB
Regulatory Filings
2025-09-01 English
Notification of cessation of securities - ATX 4 pages 14.8KB
Regulatory Filings
2025-09-01 English
Application for quotation of securities - ATX 6 pages 18.4KB
Share Issue/Capital Change
2025-08-31 English
Application for quotation of securities - ATX 6 pages 18.3KB
Share Issue/Capital Change
2025-08-31 English
Notice under Section 708A(5)(e) of the Corporations Act 2 pages 230.5KB
Capital/Financing Update
2025-08-31 English
Notification regarding unquoted securities - ATX 7 pages 22.0KB
Share Issue/Capital Change
2025-08-31 English
Notification regarding unquoted securities - ATX 7 pages 21.4KB
Share Issue/Capital Change
2025-08-31 English
Application for quotation of securities - ATX 6 pages 18.4KB
Capital/Financing Update
2025-08-28 English
AUSTRALIAN TRIAL SITES OPEN FOR NEW NARMAFOTINIB TRIAL 2 pages 184.5KB
Regulatory Filings
2025-08-28 English
Managing Director's Presentation to AGM 14 pages 3.6MB
AGM Information
2025-08-26 English
Results of Annual General Meeting 2 pages 213.2KB
Declaration of Voting Results & Voting Rights Announcements
2025-08-26 English
Amplia Share Purchase Plan Raises $2.65 Million 3 pages 254.6KB
Capital/Financing Update
2025-08-25 English
Presentation - Targeting Pancreatic Cancer and Beyond 22 pages 8.3MB
Investor Presentation
2025-08-06 English
Positive ACCENT Trial Topline Data Released 21 pages 6.1MB
Investor Presentation
2025-08-05 English
Change of Registered Office and Principal Place of Business 1
Regulatory Filings
2025-07-31 English
Share Purchase Plan Prospectus 44 pages 660.8KB
Capital/Financing Update
2025-07-31 English
Quarterly Activities/Appendix 4C Cash Flow Report 8 pages 368.4KB
Interim / Quarterly Report
2025-07-30 English
Australian Ethics Clearance for Pancreatic Cancer Trial 2 pages 184.7KB
Regulatory Filings
2025-07-29 English
Change in substantial holding 3 pages 88.7KB
Major Shareholding Notification
2025-07-29 English
Change in substantial holding 4 pages 176.8KB
Director's Dealing
2025-07-29 English
Ceasing to be a substantial holder - Blueflag Holdings 2 pages 105.4KB
Regulatory Filings
2025-07-29 English
Application for quotation of securities - ATX 6 pages 18.6KB
Share Issue/Capital Change
2025-07-28 English
Notice under Section 708A(5)(e) of the Corporations Act 2 pages 244.0KB
Capital/Financing Update
2025-07-28 English
Notice of Annual General Meeting/Proxy Form 39 pages 895.7KB
AGM Information
2025-07-24 English
Amplia announces A$25m Placement and Launches A$2.5m SPP 5 pages 278.7KB
Capital/Financing Update
2025-07-22 English
Proposed issue of securities - ATX 10 pages 31.0KB
Capital/Financing Update
2025-07-22 English
Proposed issue of securities - ATX 5 pages 18.3KB
Capital/Financing Update
2025-07-22 English
Proposed issue of securities - ATX 5 pages 18.4KB
Capital/Financing Update
2025-07-22 English
Capital Raising Presentation 52 pages 3.6MB
Investor Presentation
2025-07-22 English
Application for quotation of securities - ATX 6 pages 18.3KB
Share Issue/Capital Change
2025-07-22 English
Notice under Section 708A(5)(e) of the Corporations Act 2 pages 244.0KB
Capital/Financing Update
2025-07-22 English
Trading Halt 2 pages 186.0KB
Capital/Financing Update
2025-07-20 English
Another Partial Response in ACCENT Pancreatic Cancer Trial 2 pages 186.0KB
Regulatory Filings
2025-07-10 English
Application for quotation of securities - ATX 6 pages 18.3KB
Share Issue/Capital Change
2025-07-03 English
Additional Partial Response in Pancreatic Cancer Trial 2 pages 183.4KB
Regulatory Filings
2025-07-01 English
Annual General Meeting to be held Wednesday 27 August 2025 1
AGM Information
2025-07-01 English
Amplia Gains US Ethics Approval for Pancreatic Cancer Trial 2 pages 184.4KB
Regulatory Filings
2025-06-23 English
Second Complete Response in ACCENT Pancreatic Cancer Trial 2 pages 184.8KB
Capital/Financing Update
2025-06-18 English
Change in substantial holding 3 pages 88.4KB
Major Shareholding Notification
2025-06-18 English
Pathological Complete Response in Pancreatic Cancer Trial 2 pages 188.0KB
Regulatory Filings
2025-06-15 English
Preliminary Final Report and Annual Report YE 31 March 2025 71 pages 20.4MB
Annual Report
2025-05-29 English
2025 Corporate Governance Statement 16 pages 435.7KB
Governance Information
2025-05-29 English
Appendix 4G - Key to Corporate Governance Disclosures 14 pages 400.0KB
Governance Information
2025-05-29 English
Change in substantial holding 5 pages 197.0KB
Regulatory Filings
2025-05-15 English
ACCENT Trial Achieves Superiority over Chemotherapy Alone 2 pages 197.9KB
Regulatory Filings
2025-05-14 English
Amplia Appoints Dr Jason Lickliter as Chief Medical Officer 2 pages 185.8KB
Board/Management Information
2025-05-11 English
Quarterly Activities/Appendix 4C Cash Flow Report 7 pages 393.2KB
Interim / Quarterly Report
2025-04-29 English
ACCENT Data Update Presented at International Conference 4 pages 2.0MB
Investor Presentation
2025-04-27 English
US Clinical Trial Activities for Narmafotinib Now Underway 3 pages 197.2KB
Regulatory Filings
2025-04-08 English
Encouraging Updated Data from Pancreatic Cancer Trial 2 pages 188.4KB
Capital/Financing Update
2025-03-26 English
Type D Meeting Outcome With US Food And Drug Administration 2 pages 161.3KB
Regulatory Filings
2025-03-02 English
Listing Rule 3.11.2 - change of Exercise Price of Options 1
Capital/Financing Update
2025-02-12 English
Completion of Recruitment of ACCENT Trial 2 pages 192.4KB
Regulatory Filings
2025-01-30 English
Quarterly Activities/Appendix 4C Cash Flow Report 7 pages 364.3KB
Interim / Quarterly Report
2025-01-29 English
New Narmafotinib Data Presented at International Conference 3 pages 714.4KB
Capital/Financing Update
2025-01-19 English
Release of Shares from Voluntary Escrow 1 page 126.
Capital/Financing Update
2025-01-09 English